Printer Friendly

Celerus Diagnostics Launches Second Wave of Antibodies.

12 New Products Available for Celerus Wave System

CARPINTERIA, Calif. -- Chief Scientific Officer Marc Key, PhD, announced that Celerus Diagnostics introduced 12 new products for use on the Celerus Wave System, the first and only solution to deliver precise, standardized IHC results in 15 minutes.

"We've listened to our customers and responded with a series of antibodies adding depth and variety to our growing portfolio," said Dr. Key.

He described some of the new products.

* CD10, a cell surface antigen also known as CALLA (common acute lymphoblastic leukemia antigen), is expressed on a variety of cell types, including immature and germinal center B cells, as well as lymphoblastic leukemia cells.

* CD34 is a marker of lymphatic and vascular endothelium. Antibodies to CD34 can be used to study tumors of endothelial origin. CD34 is also a useful marker for quantifying micro-vascular density in a variety of other tumor types.

* Tyrosinase is a copper-glycoenzyme involved in the synthesis of melanin pigments. The melanin pigments can serve as markers for cells of melanocytic lineage, including malignant melanomas.

* CD117, also known as c-Kit, is present on gastrointestinal stromal tumors (GIST). CD117 is important for the differential diagnosis of GIST, and its presence is important in clinical management of patients with confirmed GIST.

Unprecedented in its ability to produce high-quality IHC results in as little as 15 minutes, the Celerus Wave System has ushered in a new era of histology testing. By providing high-quality IHC results and reflex tests in a fraction of the time normally required, the Celerus Wave System enables real-time results so patients no longer have to endure traumatic delays.

"As we continue to install systems, and with demand increasing, our laboratory is on track to release 12-15 new products quarterly in response to customer needs," said Dr. Key.

Other products included in this launch are CD7, CD8, CD30, CD43, CD79a, Cytokeratin (HMW), Cytokeratin 20 and P63.

About Celerus Diagnostics Founded in 2004 in Santa Barbara, California, Celerus Diagnostics develops innovative solutions to enhance the diagnostic capabilities of the anatomic pathology laboratory, provide clinicians with rapid, reliable, actionable diagnostic information, and advance patient care. The first Celerus Wave Systems were installed in North America and Europe in 2008.
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 24, 2009
Previous Article:National Product Search Contest Call for Entries.
Next Article:Novel Search Strategies to be Presented by NextBio at the Molecular Medicine Tri-Conference.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters